+ Watch SCLN
on My Watchlist
A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.
Seems like SciClone's share price keeps gravitating back up towards 5, despite unpredictability of future revenues due to an ongoing review of Zadaxin pricing by Chinese authorities, coincident investigations of the company by the SEC and US DOJ, and a faltering pipeline. Zadaxin revenues were actually down on a quarter-to-quarter basis. I'm neutral on the NovaMed purchase until there is more clarity on profit and the true price of the acquisition. I see the stock primed for a lovely haircut at this level when the inevitable negative catalyst emerges.
I've noticed SciClone's progress with pleasant surprise as it rises in spite of its recent baggage - but I bought it not long ago when it was in the low 3's so I'm a happy camper right now. My plan of action is to watch closely and ditch a large part at the first sign of a dribble. (why so happy about gloom and doom?)
How's the camping these days?
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions